LLY

903

-1.58%↓

JNJ

235.46

-0.93%↓

ABBV

204.23

-0.92%↓

NVS

145.89

-1.52%↓

AZN

183.37

-2.88%↓

LLY

903

-1.58%↓

JNJ

235.46

-0.93%↓

ABBV

204.23

-0.92%↓

NVS

145.89

-1.52%↓

AZN

183.37

-2.88%↓

LLY

903

-1.58%↓

JNJ

235.46

-0.93%↓

ABBV

204.23

-0.92%↓

NVS

145.89

-1.52%↓

AZN

183.37

-2.88%↓

LLY

903

-1.58%↓

JNJ

235.46

-0.93%↓

ABBV

204.23

-0.92%↓

NVS

145.89

-1.52%↓

AZN

183.37

-2.88%↓

LLY

903

-1.58%↓

JNJ

235.46

-0.93%↓

ABBV

204.23

-0.92%↓

NVS

145.89

-1.52%↓

AZN

183.37

-2.88%↓

Home・Aandelen Lijst・Avita Therapeutics Inc

Avita Therapeutics Inc

Gesloten

3.91 -2.98

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

3.85

Max

3.96

Belangrijke statistieken
By Trading Economics
Inkomsten	1.6M -12M
Verkoop	554K 18M
EPS	-0.536
Winstmarge	-65.968
Werknemers	226
EBITDA	1.6M -9.7M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+60.25% upside

Dividenden
By Dow Jones
Volgende Winsten	7 mei 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	18M 142M
Vorige openingsprijs	6.89
Vorige sluitingsprijs	3.91

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

8.83 / 9.77 Steun & Weerstand

Avita Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

22 mrt 2026, 23:50 UTC

Marktinformatie

Global Equities Roundup: Market Talk

22 mrt 2026, 23:50 UTC

Marktinformatie

LG Electronics Set to Stage Strong Earnings Rebound in 1Q -- Market Talk

22 mrt 2026, 23:49 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Gold Edges Lower on Prospects of Liquidity-Driven Sales -- Market Talk

22 mrt 2026, 23:49 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Nikkei May Fall as Concerns About Middle East Conflict Persist -- Market Talk

22 mrt 2026, 23:49 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Global Forex and Fixed Income Roundup: Market Talk

22 mrt 2026, 23:41 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Oil Edges Lower as Traders Eye Trump's Deadline to Reopen Strait of Hormuz -- Market Talk

22 mrt 2026, 22:57 UTC

Acquisities, Fusies, Overnames

Perseus Mining: Location of Aurum's Discoveries Present Potential Future Synergies

22 mrt 2026, 22:56 UTC

Acquisities, Fusies, Overnames

Perseus Mining: Aurum Share Acquisition Cost A$23.69 Million

22 mrt 2026, 22:56 UTC

Acquisities, Fusies, Overnames

Perseus Mining: Aurum's Boundiali Gold Project Located to South of Sissingue Gold Mine

22 mrt 2026, 22:55 UTC

Acquisities, Fusies, Overnames

Perseus Mining: Participated in Aurum Resources Equity Raising

22 mrt 2026, 22:54 UTC

Acquisities, Fusies, Overnames

Perseus Mining: Acquires 9.9% Interest in Aurum Resources

22 mrt 2026, 22:22 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

After Selloff, Gold Seen Supported by Strait of Hormuz Deadline -- Market Talk

22 mrt 2026, 22:06 UTC

Acquisities, Fusies, Overnames

Synopsys Has Market Value Over $80 Billion; Major Customers Include Nvidia -- WSJ

22 mrt 2026, 22:06 UTC

Acquisities, Fusies, Overnames

Activist Elliott Builds Big Stake in Chip-Design Software Maker Synopsys -- WSJ

22 mrt 2026, 22:06 UTC

Acquisities, Fusies, Overnames

Activist Elliott Investment Management Has Multibillion-Dollar Investment in Synopsys, Sources Say -- WSJ

22 mrt 2026, 22:06 UTC

Acquisities, Fusies, Overnames

Elliott Plans to Push Synopsys to Make More Money From Its Software and Services, Sources Say -- WSJ

22 mrt 2026, 21:53 UTC

Winsten

Zijin Gold International Plans 59.2 Tons of Gold Production in 2026; up 12.3% on Year >2259.HK

22 mrt 2026, 21:53 UTC

Winsten

Zijin Gold International Rising Gold Prices Supported Results >2259.HK

22 mrt 2026, 21:53 UTC

Winsten

Zijin Gold International 2025 Rev $5.38B Vs. $2.99B >2259.HK

22 mrt 2026, 21:53 UTC

Winsten

Zijin Gold International 2025 Net $1.60B Vs. Net $481.37M >2259.HK

22 mrt 2026, 21:31 UTC

Winsten

China Petroleum & Chemical Plans CNY131.6B-CNY148.6B Capex Spending in 2026>0386.HK

22 mrt 2026, 21:31 UTC

Winsten

China Petroleum & Chemical: Decrease in Sales Volumes of Refined Oil Products Also Hurt Results >0386.HK

22 mrt 2026, 21:31 UTC

Winsten

China Petroleum & Chemical 2025 Results Weighed by Decrease in Prices of Petroleum, Petrochemical Products>0386.HK

22 mrt 2026, 21:31 UTC

Winsten

China Petroleum & Chemical 2025 Rev CNY2.78T Vs. CNY3.07T >0386.HK

22 mrt 2026, 21:31 UTC

Winsten

China Petroleum & Chemical 2025 Net CNY32.48B Vs. Net CNY48.94B >0386.HK

22 mrt 2026, 21:25 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Bonds Decoupling From Oil Amid Longer Conflict Fears -- Market Talk

22 mrt 2026, 21:22 UTC

Acquisities, Fusies, Overnames

St Barbara: Remarks Follow Recent Inquiries About Simberi's Fuel Stocks

22 mrt 2026, 21:21 UTC

Acquisities, Fusies, Overnames

St Barbara: Simberi Currently Uses About 65,000 Liters Per Day For Mining Fleet, Power Generation

22 mrt 2026, 21:21 UTC

Marktinformatie

Revised Fuel Subsidy Mechanism Positive for Ampol, Viva Energy -- Market Talk

22 mrt 2026, 21:21 UTC

Acquisities, Fusies, Overnames

St Barbara: Has Been Taking Precaution to Increase Diesel Storage For Several Months

Peer Vergelijking

Prijswijziging

Avita Therapeutics Inc Prognose

Koersdoel

By TipRanks

60.25% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 6.33 USD 60.25%

Hoogste 10 USD

Laagste 3.5 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor Avita Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

4 ratings

Buy

Hold

Sell

Gebaseerd op 4 analisten die aandelenratings hebben gegeven aan Avita Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

8.83 / 9.77Steun & Weerstand

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Avita Therapeutics Inc

AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.